Key Summary
- PharmBot AI submitted written evidence detailing the role of AI in pharmacy to the UK Parliament.
- It includes real-world deployment data from 76 Pharmacy First consultations.
- The company says community pharmacy remains underrepresented in national digital health policy.
PharmBot AI has submitted written evidence to the House of Lords Science and Technology Committee as part of its ongoing inquiry into “Innovation in the NHS: Personalised Medicine and Artificial Intelligence.”
The UK-based clinical AI company developing AI-enabled decision support infrastructure for pharmacy presented evidence on the role of AI-assisted clinical workflows in community pharmacy.
Despite serving millions of patients across England every day through approximately 10,000 pharmacies, has received comparatively limited attention in national digital health policy.
The submission noted that digital innovation in community pharmacy remains relatively limited compared with other areas of healthcare, and argues that this represents a missed opportunity for the NHS.
The evidence documents the deployment of AIVAe, PharmBot AI's clinical assistant platform, across 76 structured clinical consultations within the NHS Pharmacy First programme.
Preliminary analysis of those consultations indicates a time saving of approximately 15 to 20 minutes per consultation, alongside improvements in the consistency and completeness of clinical documentation.
The company says community pharmacy remains underrepresented in national digital health policy, despite its scale and daily contact with millions of patients.
Asif Mukhtar, Founder and CEO of PharmBot AI, said: "The inquiry is asking exactly the right question not whether AI works in a laboratory, but why it so rarely works in practice inside the NHS.
“Our submission offers a specific, grounded answer from community pharmacy: AI fails when it is built outside clinical workflows and deployed into them afterwards. Community pharmacy serves more patients more regularly than almost any other part of the NHS, yet it is consistently absent from these policy conversations.
“We hope this submission helps to change that. The evidence from our Pharmacy First consultations suggests that when AI is genuinely embedded in the workflow from the outset, the benefits are measurable and meaningful."
The company said that clinical governance must be the foundation of responsible AI use, not an afterthought.
The House of Lords Science and Technology Committee launched the inquiry in March 2026 to examine why the NHS struggles to adopt UK life sciences innovations, using personalised medicine and AI as a case study.
